Skip to content
Screener

BridgeBio Pharma BBIO Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$194.5MBeat by $16.4M
EPS-$0.84Miss by $0.14
Revenue estimate$178.1M
EPS estimate-$0.70

Next report

Oct 28, 2026 (in 2 months)
Revenue estimate$267.3M
EPS estimate-$0.67

Financials

Q1 2026

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$14.4B+119%
Enterprise value$16.77B+178%
P/S24.8×-26.8×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Current ratio1.5×-3.0×

Segments

By product

See full
Cost of license, services, and royalty revenue$10.3M—
License and services revenue$4.4M—

By segment

See full
Reportable Segment$194.5M—

FAQ

When did BridgeBio Pharma report Q1 2026 earnings?
BridgeBio Pharma (BBIO) reported Q1 2026 earnings on May 7, 2026 after market close.
What were BridgeBio Pharma's Q1 2026 revenue and EPS?
BridgeBio Pharma reported revenue of $194.5M and eps of $-0.84 for Q1 2026.
Did BridgeBio Pharma beat estimates in Q1 2026?
Revenue beat the consensus estimate of $178.1M by $16.4M. EPS missed the consensus estimate of $-0.70 by $0.14.
How did BridgeBio Pharma's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 66.8% from $116.6M a year earlier and eps grew 4.5% from $-0.88.
Where can I find BridgeBio Pharma's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001743881-26-000018) and the 10-Q periodic report (0001743881-26-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.